INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,563 | +25.0% | 3,126 | +137.9% | 0.00% | – |
| Q4 2022 | $2,050 | -48.8% | 1,314 | -32.6% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 1,950 | -20.9% | 0.00% | – |
| Q2 2022 | $4,000 | +100.0% | 2,466 | +328.9% | 0.00% | – |
| Q1 2022 | $2,000 | +100.0% | 575 | +2111.5% | 0.00% | – |
| Q3 2020 | $1,000 | -100.0% | 26 | -100.0% | 0.00% | -100.0% |
| Q2 2020 | $2,633,000 | +131550.0% | 97,696 | +45129.6% | 0.01% | – |
| Q1 2020 | $2,000 | 0.0% | 216 | -72.1% | 0.00% | – |
| Q3 2019 | $2,000 | -83.3% | 775 | -81.4% | 0.00% | – |
| Q2 2019 | $12,000 | -25.0% | 4,166 | 0.0% | 0.00% | – |
| Q1 2019 | $16,000 | -96.4% | 4,166 | -96.2% | 0.00% | -100.0% |
| Q4 2018 | $440,000 | +4788.9% | 109,898 | +6755.8% | 0.00% | – |
| Q3 2018 | $9,000 | +12.5% | 1,603 | -12.5% | 0.00% | – |
| Q4 2017 | $8,000 | -33.3% | 1,833 | -2.6% | 0.00% | – |
| Q3 2017 | $12,000 | – | 1,882 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Green Alpha Advisors, LLC | 570,049 | $221,749 | 0.17% |
| GMT CAPITAL CORP | 1,513,500 | $588,752 | 0.02% |
| Cedar Brook Financial Partners, LLC | 130,522 | $50,773 | 0.01% |
| Arlington Capital Management, Inc. | 27,735 | $10,789 | 0.01% |
| GSA CAPITAL PARTNERS LLP | 296,948 | $116 | 0.01% |
| Keystone Financial Group | 109,897 | $42,751 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 163,562 | $63,626 | 0.00% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,149,974 | $447,340 | 0.00% |
| Freedom Investment Management, Inc. | 62,298 | $24,234 | 0.00% |
| Renaissance Technologies | 4,889,500 | $1,902 | 0.00% |